TriNetra-Glio is a revolutionary, non-invasive liquid biopsy blood test designed to diagnose high-grade brain tumors, including glioblastoma (GBM), by detecting circulating tumor cells in the blood. It received FDA Breakthrough Device Designation in 2023, offering a faster, safer alternative to surgical biopsies, particularly for inaccessible tumors.
___
TriNetra-Glio glioblastoma
+7
TriNetra-Glio is a revolutionary, non-invasive liquid biopsy blood test designed to diagnose high-grade brain tumors, including glioblastoma (GBM), by detecting circulating tumor cells in the blood.
It received FDA Breakthrough Device Designation in 2023, offering a faster, safer alternative to surgical biopsies, particularly for inaccessible tumors.
Imperial College Healthcare NHS Trust
+4
Key Aspects of TriNetra-Glio for Glioblastoma:
Technology:
The test isolates, stains, and identifies rare circulating glial cells that have broken away from the main tumor and are present in a small blood sample.
Clinical Utility:
It is intended for patients with intracranial lesions where a biopsy is not possible, too risky, or has yielded non-diagnostic results.
Advantages:
Early Diagnosis:
Enables quicker diagnosis, potentially reducing the wait time for treatment, which is critical for aggressive GBM (often with a 12-month prognosis)
.
Safety:
Replaces the need for high-risk surgical biopsies.
Accuracy: Studies have indicated high accuracy in detecting malignant glioma cells.
Impact:
This test is seen as a major shift from traditional surgical approaches, aimed at Improving care and increasing survival rates by enabling earlier, targeted treatment.
Developed in collaboration with Imperial College London.
___
TriNetra-Glio glioblastoma
+7
TriNetra-Glio is a revolutionary, non-invasive liquid biopsy blood test designed to diagnose high-grade brain tumors, including glioblastoma (GBM), by detecting circulating tumor cells in the blood.
It received FDA Breakthrough Device Designation in 2023, offering a faster, safer alternative to surgical biopsies, particularly for inaccessible tumors.
Imperial College Healthcare NHS Trust
+4
Key Aspects of TriNetra-Glio for Glioblastoma:
Technology:
The test isolates, stains, and identifies rare circulating glial cells that have broken away from the main tumor and are present in a small blood sample.
Clinical Utility:
It is intended for patients with intracranial lesions where a biopsy is not possible, too risky, or has yielded non-diagnostic results.
Advantages:
Early Diagnosis:
Enables quicker diagnosis, potentially reducing the wait time for treatment, which is critical for aggressive GBM (often with a 12-month prognosis)
.
Safety:
Replaces the need for high-risk surgical biopsies.
Accuracy: Studies have indicated high accuracy in detecting malignant glioma cells.
Impact:
This test is seen as a major shift from traditional surgical approaches, aimed at Improving care and increasing survival rates by enabling earlier, targeted treatment.
Developed in collaboration with Imperial College London.
3
